All In Biotech

Drug Trial Radar · NCT00175877

A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

A Phase III Multi-centre, Open-label, follow-on Study to CDP870-027, to Assess the Efficacy and Safety of Lyophilized CDP870 an Engineered Human Anti-TNF PEG Conjugate, as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Mar 26, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

857

Actual

Start

Jun 2005

Primary completion

Feb 2012

Study completion Feb 2012

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Sep 15, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open ended study in which patients who completed the double-blind study CDP870-027 \[NCT00152386\] are given Certolizumab Pegol (CZP) and assessed for signs and symptoms of Rheumatoid Arthritis (RA).

Conditions

  • Rheumatoid Arthritis

Interventions

  • Certolizumab PegolBiological

    Strength and Form: Lyophilized product reconstituted to 1 ml containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection. Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks. Duration: Until end of study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With at Least One Adverse Event (AE) From First Certolizumab Pegol (CZP) Dose up to Approximately 7 YearsTime frame: From first dose of CZP to the end of the open-label study (approximately 7 years)
  2. Percentage of Subjects With at Least One Serious Adverse Event (SAE) From First Certolizumab Pegol (CZP) Dose up to Approximately 7 YearsTime frame: From first dose of CZP to the end of the open-label study (approximately 7 years)
  3. Percentage of Subjects Who Withdrew Due to an Adverse Event (AE) During the StudyTime frame: From Entry Visit (Week 0) to the end of the study (approximately 6.5 years)

Locations

121 sites in 22 countries. Site status is shown where the registry gives one.

  • 152

    Huntsville, Alabama

  • 148

    San Diego, California

  • 153

    Danbury, Connecticut

  • 133

    Ocala, Florida

  • 140

    Orlando, Florida

  • 150

    Orlando, Florida

  • 145

    Sarasota, Florida

  • 136

    Tampa, Florida

  • 157

    Coeur d'Alene, Idaho

  • 155

    Springfield, Illinois

  • 134

    Wheaton, Maryland

  • 151

    St Louis, Missouri

  • 156

    Lincoln, Nebraska

  • 135

    Charlotte, North Carolina

  • 147

    Cleveland, Ohio

  • 158

    Dayton, Ohio

  • 139

    Charleston, South Carolina

  • 137

    Austin, Texas

  • 143

    San Antonio, Texas

  • 12

    Buenos Aires, Argentina

  • 14

    Capital Federal, Argentina

  • 1

    Capital Federal, Argentina

  • 9

    Capital Federal, Argentina

  • 8

    Ciudad Autonoma de Buenos Aire, Argentina

  • 11

    Córdoba, Argentina

  • 2

    Córdoba, Argentina

  • 13

    Quilmes, Argentina

  • 7

    Rosario, Argentina

  • 10

    San Miguel de Tucumán, Argentina

  • 6

    Santa Fe, Argentina

  • 18

    Malvern, Australia

  • 21

    Maroochydore, Australia

  • 23

    Perth, Australia

  • 179

    Antwerp, Belgium

  • 199

    Liège, Belgium

  • 177

    Merksem, Belgium

  • 29

    Pleven, Bulgaria

  • 221

    Sofia, Bulgaria

  • 28

    Sofia, Bulgaria

  • 30

    Sofia, Bulgaria

Showing 40 of 121 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.